Prosecution Insights
Prosecution Insights
20 pending office actions • 12 art units • 19 examiners • 0 of 20 (0%) have an AI response strategy ready • 52 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 20 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 20 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 8 (40%) |
| §102 only | 1 (5%) |
| §112 only | 3 (15%) |
| No statute on record | 8 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| AULAKH, CHARANJIT | 2 | 80.9% | -15.6% |
| BERRY, LAYLA D | 1 | 65.9% | +8.6% |
| CHAO, ALLEN | 1 | 100.0% | +0.0% |
| OLSON, ANDREA STEFFEL | 1 | 62.2% | -12.5% |
| DENT, ALANA HARRIS | 1 | 44.6% | +32.4% |
| LEWIS, PATRICK T | 1 | 74.3% | +14.5% |
| GRIZER, CASSANDRA SENN | 1 | 100.0% | +0.0% |
| BORALSKY, LUKE ALAN | 1 | 100.0% | +0.0% |
| DEKARSKE, MADELINE MCGUIRE | 1 | — | — |
| SEITZ, ANTHONY JOSEPH | 1 | 68.8% | +28.3% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18512088 | METHODS FOR TREATING POXVIRUS INFECTIONS | CHAO, ALLEN | 3d overdue |
| 18448721 | DOSING AND SCHEDULING REGIMEN FOR BROADLY NEUTRALIZING ANTIBODIES | GRIZER, CASSANDRA SENN | 8d |
| 18264670 | THIENOPYRROLE COMPOUNDS | AULAKH, CHARANJIT | 70d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18243812 | METHODS FOR TREATMENT OF VIRAL INFECTIONS | LEWIS, PATRICK T | 25d overdue |
| 18469844 | FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY | DENT, ALANA HARRIS | 12d |
| 18344560 | CD73 COMPOUNDS | SEITZ, ANTHONY JOSEPH | 69d |
| Art Unit | Apps |
|---|---|
| 1693 | 3 |
| 1622 | 3 |
| 1621 | 2 |
| 1691 | 2 |
| 1672 | 2 |
| 1627 | 2 |
| 1643 | 1 |
| 1624 | 1 |
| 1629 | 1 |
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18740078 | QUINOLINE DERIVATIVES | AULAKH, CHARANJIT | 1621 | Other | Non-Final OA | 103d overdue | Pending | Jun 11, 2024 |
| 18655876 | METHODS OF PREPARING 1'-CYANO NUCLEOSIDES | BERRY, LAYLA D | 1693 | §103 | Non-Final OA | 5d overdue | Pending | May 06, 2024 |
| 18512088 | METHODS FOR TREATING POXVIRUS INFECTIONS | CHAO, ALLEN | 1622 | §103 | Non-Final OA | 3d overdue | Pending | Nov 17, 2023 |
| 18479576 | 4'-THIONUCLEOSIDE ANALOGUES AND THEIR PHARMACEUTICAL USE | OLSON, ANDREA STEFFEL | 1693 | §103 | Non-Final OA | 9d overdue | Pending | Oct 02, 2023 |
| 18469844 | FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY | DENT, ALANA HARRIS | 1643 | §103 | Non-Final OA | 12d | Pending | Sep 19, 2023 |
| 18243812 | METHODS FOR TREATMENT OF VIRAL INFECTIONS | LEWIS, PATRICK T | 1691 | §103 | Non-Final OA | 25d overdue | Pending | Sep 08, 2023 |
| 18448721 | DOSING AND SCHEDULING REGIMEN FOR BROADLY NEUTRALIZING ANTIBODIES | GRIZER, CASSANDRA SENN | 1672 | §103 | Non-Final OA | 8d | Pending | Aug 11, 2023 |
| 18264670 | THIENOPYRROLE COMPOUNDS | AULAKH, CHARANJIT | 1621 | §102 | Final Rejection | 70d | Pending | Aug 08, 2023 |
| 18365919 | SARS-COV2 MAIN PROTEASE INHIBITORS | BORALSKY, LUKE ALAN | 1624 | Other | Non-Final OA | 6d | Pending | Aug 04, 2023 |
| 18345547 | THERAPEUTIC COMPOUNDS USEFUL FOR THE PROPHYLACTIC OR THERAPEUTIC TREATMENT OF AN HIV VIRUS INFECTION | DEKARSKE, MADELINE MCGUIRE | 1622 | Other | Non-Final OA | 8d overdue | Pending | Jun 30, 2023 |
| 18344560 | CD73 COMPOUNDS | SEITZ, ANTHONY JOSEPH | 1629 | §112 | Final Rejection | 69d | Pending | Jun 29, 2023 |
| 18268440 | SUBSTITUTED INDOLE COMPOUNDS | REILLY, SOPHIA JANE | 1627 | Other | Final Rejection | 22d overdue | Pending | Jun 20, 2023 |
| 18313266 | DARUNAVIR COMBINATION FORMULATIONS | LEE, ANDREW P | 1691 | Other | Final Rejection | 26d overdue | Pending | May 05, 2023 |
| 18303813 | KRAS G12D MODULATING COMPOUNDS | SANCHEZ, JUSTIN CHRISTOPHER | 1622 | §112 | Non-Final OA | 1d overdue | Pending | Apr 20, 2023 |
| 18296296 | ENGINEERED CD200R ANTIBODIES AND USES THEREOF | HOWARD, ZACHARY C | 1674 | §112 | Non-Final OA | 22d overdue | Pending | Apr 05, 2023 |
| 18295163 | COMBINATION THERAPY FOR TREATING COLORECTAL CANCER | TRAN HO, LAM THUY VI | 1647 | Other | Non-Final OA | 2d overdue | Pending | Apr 03, 2023 |
| 18176864 | ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | CHO, DAVID H | 1693 | Other | Non-Final OA | 100d overdue | Pending | Mar 01, 2023 |
| 17997594 | CD73 COMPOUNDS | NESTOR, DONNA MICHELLE | 1627 | Other | Final Rejection | 131d overdue | Pending | Oct 31, 2022 |
| 17636511 | PHARMACEUTICAL FORMULATIONS OF TENOFOVIR ALAFENAMIDE | JACKSON, SHAWQUIA | 1626 | §103 | Non-Final OA | 77d | Pending | Feb 18, 2022 |
| 17612426 | DOSAGE REGIMENS FOR VACCINES | JADHAO, SAMADHAN JAISING | 1672 | §103 | Non-Final OA | 31d overdue | Pending | Nov 18, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial